Most new HIV infections occurred outside sub-Saharan Africa for first time – UN report
GuardianJUL 2024
It is still to early for Gilead to be able to predict what the cost for Lenacapavir as a PrEP will be. The research presented on Tuesday has not been peer reviewed, and thus while it is hopeful, it should not be given too much weight. Despite this, Gilead is working to ensure that the drug will be widely accessible in the future.